Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 11, 2007, Pages 843-845

  Rieger, C ^a   Geiger, S ^a   Herold, T ^a   Nickenig, C ^a   Ostermann, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukaemia; Breakthrough infection; Posaconazole; Trichosporon

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYTARABINE; DAUNORUBICIN; MEROPENEM; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; TIOGUANINE; VANCOMYCIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; SYMPTOM; TRICHOSPORON ASAHII; VIRUS PNEUMONIA;

AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CROSS INFECTION; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYCOSES; PYRIMIDINES; TRIAZOLES; TRICHOSPORON;

EID: 35348861860     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0366-5     Document Type: Article

References (10)

1. Paphitou NI, Ostrosky-Zeichner L, Paetznick V, Rodriguez JR, Chen E, Rex JH (2002) In vitro antifungal susceptibility of Trichosporon species. Anitmicrob Agents Chemother 46:1144-1146
2. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al (2007) Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348-359
3. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335-347
4. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2-12
5. Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D'Antonio D, Piccolomini R (2006) Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob Agents Chemother 50:3269-3276
6. Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, et al (1992) Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 15:781-787
7. Spanakis E, Aperis G, Mylonakis E (2006) New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 43:1060-1068
8. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, et al (2004) Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum, and determinants of outcome. Scand J Infect Dis 36:564-569
9. Krcmery V Jr, Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z, et al (1999) Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during intraconazole. Support Care Cancer 7:39-43
10. Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, et al (2002) Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microb Infect Dis 21:892-896